Drug Trial Radar · NCT00906880
Clinical Study to Assess the Tolerability, Feasibility and Effectiveness of Nifurtimox and Eflornithine (NECT) for the Treatment of Trypanosoma Brucei Gambiense Human African Trypanosomiasis (HAT) in the Meningo-encephalitic Phase
Last checked: Nov 20, 2026Latest source record: May 31, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
630
Actual
Start
Apr 2009
Primary completion
Sep 2010
Study completion Jan 2013
Sponsor
- Lead sponsor
- Drugs for Neglected DiseasesAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Ministry of Public Health, Democratic Republic of the Congo; Swiss Tropical & Public Health Institute
- First posted
- May 21, 2009
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Multicenter, open label, uncontrolled phase IIIb study of therapeutic use of the combination of nifurtimox and eflornithine (NECT) for the treatment of Trypanosoma brucei gambiense human African trypanosomiasis (HAT) in the meningo-encephalitic phase. Overall objectives: Assess the clinical tolerability, feasibility and effectiveness of NECT co-administration to treat patients with T.b. gambiense human African trypanosomiasis (HAT) in the meningo-encephalitic phase in actual real-life conditions (regular treatment centers of the National HAT Control Programme, NGO treatment centers). Primary objective: * Assess the clinical response of the NECT co-administration under field conditions. Secondary objectives: * Assess the incidence and type of adverse events (AE), and the capacity of the treatment centers to deal with these. * Assess the feasibility of the implementation of the NECT coadministration by the health center. * Assess the effectiveness of the NECT co-administration at 24\* months after treatment.
Conditions
- Human African Trypanosomiasis
Interventions
Nifurtimox-Eflronithine Combination Treatment (NECT)Drug
co-administration of nifurtimox (10 days, 15 mg/kg/day, p.o. TID) and eflornithine (7 days, 400 mg/kg/day, i.v. BID)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of patients discharged alive from the hospital or the treatment center
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
HGR (General Reference Hospital) Bandundu
Bandundu, Bandundu, Republic of the Congo
HGR (General Reference Hospital) Kwamouth
Kwamouth, Bandundu, Republic of the Congo
HGR (General Reference Hospital) Yasa Bonga
Yasa Bonga, Bandundu, Republic of the Congo
CDTC (Centre de Dépistage, Traitement et Contrôle) Katanda
Katanda, East Kasai, Republic of the Congo
CRT (Centre de Réference et de Traitement) Dipumba, Dipumba general hospital
Mbuji Mayi, East Kasai, Republic of the Congo
HGR (General Reference Hospital) Ngandajika
Ngandajika, East Kasai, Republic of the Congo
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.